Search results
Zumutor is a leading Immuno-Oncology company in the space of targeted NK cell therapeutics. Our proprietary Human Antibody platform INABLR ™ is the genesis to our wholly owned, first-in-class therapeutic antibodies which target innate immunity and regulate the tumor micro environment.
Sep 14, 2022 · Syngene International, a leading global Contract Research Services Company, has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immunooncology Company, to access Zumutor’s proprietary naïve human phage/yeast display library.
Zumutor Biologics | 6,018 followers on LinkedIn. A leading Immuno Oncology company in the space of NK cell therapeutics | At Zumutor, we are on a mission to develop novel novel immuno...
Apr 8, 2021 · Zumutor has developed multiple expression platforms which lead to improvement of antibody dependent cellular cytotoxicity of therapeutic antibodies. The ADCC Improvement Platform and methods of development are unique and we have filed patent applications to secure global IP rights.
Jun 12, 2024 · BOSTON and BANGALORE, India, June 12, 2024 /PRNewswire/ -- Zumutor Biologics Inc. "Zumutor", a Boston -based clinical stage Oncology Company developing first-in-class monoclonal antibody...
Jun 12, 2024 · Zumutor is a novel immuno therapeutics company driving transformational change by harnessing the power of NK cells in modulating the Tumor Micro Environment (TME).
Aug 12, 2023 · Zumutor is a novel immuno therapeutics company driving transformational change by harnessing the power of NK cells in modulating the Tumor Micro Environment (TME).
